leisure time -WSS

leisure time

author：hotspot 2025-10-02 23:30:30 - browse：49

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： The biotech scorecard for Q3: 15 stock

WSS

Crowdfunding for unproven stem cell procedures spreads misinformation

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

WHO may add ‘noma' to its list of neglected tropical diseases

Hubble vs. James Webb telescope images: See the difference

STAT wants to know your pick for a great summer read or listen

CDC recommends rationing of RSV shot due to shortages

explore

leisure time

leisure time

Drug repurposing or repositioning? The language matters

Senate panel to vote on hospitals, PBMs, prisoner care

Sports medicine is finally prioritizing gender equality

STAT wants to know your pick for a great summer read or listen

New air purifier tech could be key to improving indoor air quality

WHO may add ‘noma' to its list of neglected tropical diseases

Anesthesiologist group: stop taking Ozempic before surgery

Skip the lead apron during X

Moonlake's readout produced a cash windfall. Risks remain

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Wikipedia

Testing for cancer recurrence creates a new limbo for patients

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Physician subsidies by hospitals soar in wake of No Surprises Act

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Traditional Chinese medicine benefits explored in new JAMA study

Undocumented workers face uncertainty as immigration law takes effect in Florida

knowledge

leisure time

explore

focus